Neurogen's NGD 91-3 misses Phase IIa endpoint

NRGN said its NGD 91-3

Read the full 56 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE